KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables: 2020-2024

Historic Receivables for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $33.6 million.

  • AbCellera Biologics' Receivables rose 127.10% to $71.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.5 million, marking a year-over-year increase of 79.95%. This contributed to the annual value of $33.6 million for FY2024, which is 9.89% up from last year.
  • Latest data reveals that AbCellera Biologics reported Receivables of $33.6 million as of FY2024, which was up 9.89% from $30.6 million recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Receivables ranged from a high of $425.6 million in FY2020 and a low of $30.6 million during FY2023.
  • For the 3-year period, AbCellera Biologics' Receivables averaged around $34.3 million, with its median value being $33.6 million (2024).
  • Per our database at Business Quant, AbCellera Biologics' Receivables plummeted by 75.97% in 2022 and then increased by 9.89% in 2024.
  • Over the past 5 years, AbCellera Biologics' Receivables (Yearly) stood at $425.6 million in 2020, then tumbled by 62.27% to $160.6 million in 2021, then crashed by 75.97% to $38.6 million in 2022, then dropped by 20.74% to $30.6 million in 2023, then increased by 9.89% to $33.6 million in 2024.